All In Biotech

Drug Trial Radar · NCT03110562

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

402

Actual

Start

May 24, 2017

Primary completion

Feb 18, 2020

Study completion May 12, 2022

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Apr 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.

Conditions

  • Multiple Myeloma

Interventions

  • SelinexorDrug

    oral 100 mg dose

  • BortezomibDrug

    subcutaneous dose of 1.3 mg/m2

  • DexamethasoneDrug

    oral dose of 20mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)Time frame: From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)

Locations

157 sites in 21 countries. Site status is shown where the registry gives one.

  • Boca Raton Clinical Research (BRCR) Medical Center

    Plantation, Florida

  • Emory University

    Atlanta, Georgia

  • Kaiser Permanente Hawaii

    Honolulu, Hawaii

  • McFarland Clinic

    Ames, Iowa

  • Stormont Vail Health Care (Cotton O'Neil Cancer Center )

    Topeka, Kansas

  • Commonwealth Hematology

    Danville, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • University of Maryland

    Baltimore, Maryland

  • Central Care Cancer Center

    Bolivar, Missouri

  • The Valley Hospital Luckow Pavilion

    Paramus, New Jersey

  • Mount Sinai

    New York, New York

  • The Cancer Institute at St. Francis Hospital

    Roslyn, New York

  • Novant-Forsyth Memorial Hospital

    Winston-Salem, North Carolina

  • University of Cincinnati Health

    Cincinnati, Ohio

  • Southwest Cancer Center of Oklahoma

    Lawton, Oklahoma

  • Kaiser Permanente Northwest OR

    Portland, Oregon

  • SCOR AnMed Health Cancer Center

    Anderson, South Carolina

  • Prairie Lakes Healthcare

    Watertown, South Dakota

  • Baylor Sammons Cancer Center

    Dallas, Texas

  • University of Texas Southwestern

    Dallas, Texas

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Mater Misericordiae Limited and Mater Medical Research

    South Brisbane, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)

    Innsbruck, Austria

  • University Hospital Krems, Department of Internal Medicine II

    Krems, Austria

  • Medical University of Vienna

    Vienna, Austria

  • General Hospital Hietzing

    Vienna, Austria

  • Wilhelminen Hospital, Department of Internal Medicine I, Center for Oncology & Hematology

    Vienna, Austria

  • Jules Bordet Institute

    Brussels, Belgium

  • UCL Saint-Luc

    Brussels, Belgium

  • University Hospital Ghent

    Ghent, Belgium

  • General Hospital Delta

    Roeselare, Belgium

  • St. Augustinus Hospital

    Wilrijk, Belgium

  • University Multiprofile Hospital for Active Treatment, Sveti Georgi Clinic of Clinical Hematology

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment, Sveti Ivan Rilski Clinic of Hematology

    Sofia, Bulgaria

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.